bioAffinity Technologies Announces Annual Meeting of Stockholders on June 4, 2024

TL;DR

<b>bioAffinity Technologies will host its Annual Meeting of Stockholders on June 4, 2024, to discuss progress in noninvasive lung cancer diagnostics.</b>

AI Summary

bioAffinity Technologies, Inc. (BIAFW) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. bioAffinity Technologies, Inc. will hold its Annual Meeting of Stockholders on Tuesday, June 4, 2024, at 8:00 a.m. Central Time. The meeting will be held in person at the Company's principal office in San Antonio, Texas. The company is focused on developing noninvasive diagnostics for lung cancer and other lung diseases. President and CEO Maria Zannes expressed encouragement regarding the adoption of their lung cancer test, CyPath® Lung. Stockholders are urged to vote their shares by proxy via internet, telephone, or mail, regardless of attendance.

Why It Matters

For investors and stakeholders tracking bioAffinity Technologies, Inc., this filing contains several important signals. The annual meeting is a key event for shareholders to receive updates on the company's strategic direction and financial performance. The company's focus on noninvasive diagnostics like CyPath® Lung addresses a critical need in early cancer detection, potentially impacting patient outcomes and healthcare costs.

Risk Assessment

Risk Level: low — bioAffinity Technologies, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational disclosures that would indicate significant risk.

Analyst Insight

Review the proxy statement for details on board nominations, executive compensation, and any shareholder proposals to inform your voting decision.

Key Numbers

• June 4, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders.)
• 8:00 a.m. Central Time — Annual Meeting Time (Time of the Annual Meeting of Stockholders.)

Key Players & Entities

• bioAffinity Technologies, Inc. (company) — Registrant and filer of the proxy statement.
• Maria Zannes (person) — President and Chief Executive Officer of bioAffinity Technologies.
• CyPath® Lung (product) — The company's noninvasive test for lung cancer.
• June 4, 2024 (date) — Date of the Annual Meeting of Stockholders.
• San Antonio, Texas (location) — Location of the company's principal office and the annual meeting.

FAQ

Industry Context

The company operates in the biotechnology sector, focusing on the development of diagnostic tools for diseases of the lung.

Regulatory Implications

The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder meetings.

What Investors Should Do

1. Review the proxy statement for details on director nominees and executive compensation.
2. Understand any shareholder proposals and the board's recommendations.
3. Vote your shares by the deadline to ensure your voice is heard.

Key Dates

• 2024-06-04: Annual Meeting of Stockholders — Key date for shareholders to receive company updates and vote on corporate matters.

Year-Over-Year Comparison

This filing is a definitive proxy statement (DEF 14A) for the upcoming annual meeting, following standard SEC reporting procedures.

Key Financial Figures

• $0.007 — Company&rsquo;s common stock, par value $0.007 per share (the &ldquo; Common Stock &rd

Filing Documents

• formdef14a.htm (DEF 14A) — 952KB
• ba_logo1.jpg (GRAPHIC) — 23KB
• formpre14a_002.jpg (GRAPHIC) — 2KB
• formpre14a_004.jpg (GRAPHIC) — 2KB
• formpre14a_006.jpg (GRAPHIC) — 2KB
• proxy_001.jpg (GRAPHIC) — 317KB
• proxy_002.jpg (GRAPHIC) — 260KB
• 0001493152-24-014522.txt (&nbsp;) — 1787KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to &sect;240.14a-12 bioAffinity Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. bioAffinity Technologies, Inc. 22211 West Interstate 10, Suite 1206 San Antonio, Texas 78257 April 15, 2024 Dear Stockholder: I am pleased to invite you to attend the Annual Meeting of Stockholders of bioAffinity Technologies, Inc. on Tuesday, June 4, 2024, at 8:00 a.m. Central Time. The Annual Meeting will be held in person at the Company&rsquo;s principal office at 22211 West Interstate 10, Suite 1206, San Antonio, Texas 78257. bioAffinity Technologies is committed to developing noninvasive diagnostics for lung cancer and other diseases of the lung. Our team of scientists and business professionals is driven by its mission to increase detection of cancer at early stage when accurate diagnosis leads to longer lives, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. As President and Chief Executive Officer of bioAffinity Technologies, I am greatly encouraged by the growing adoption and use by physicians of our first test, CyPath &reg; Lung, a noninvasive test for lung cancer, and of the technological advancements that our team continues to make in its fight to address the urgent need for noninvasive, early-stage diagnosis. Whether or not you plan to attend the Annual Meeting, your vote matters. We encourage you to promptly vote your shares by proxy over the internet, via telephone or by mail. Your trust in our team and belief in our technology are invaluable. On behalf of our Board of Directors, our executive leadership team, and our dedicated team of scientists and businesspeople, we extend our sincerest gratitude for your continued support of and investment in bioAffinity Technologies. Sincerely, Maria Zannes President and Chief Executive Officer NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 4, 2024 Notice is hereby given that bioAffinity Technologies, Inc. (the &ldquo; Company &rdquo;) will host its Annual Meeting of Stockholders on Tuesday, June 4, 2024, at 8:00 a.m. Central Time (the &ldquo; Annual Meeting &rdquo;). The Annual Meeting will be held in person at the Company&rsquo;s principal office at 22211 West Interstate 10, Suite 1206, San Antonio, Texas 78257. The Annual Meeting is being held for the following purposes: (1) To elect the eight director nominees listed in the accompanying Proxy Statement to serve until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified; (2) To consider and approve the bioAffinity Technologies, Inc. 2024 Incentive Compensation Plan (the &ldquo; 2024 Plan &rdquo;); (3) To consider and approve an amendment to the Company&rsquo;s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 25,000,000 shares to 100,000,000 shares (&ldquo; Increase In Authorized Shares Proposal &rdquo;); (4) To ratify the appointment of WithumSmith+Brown, PC as the Company&rsquo;s independent registered public accounting firm for the fiscal year ending December 31, 2024; (5) To approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 1,632,000 shares of our common stock upon the exercise of our common stock purchase warrants issued to institutional investors and designees of the placement agent in connection with our private placement offering that closed on March 8, 2024, that may be equal to or exceed 20% of our common stock outstanding before such offering (the &ldquo; Warrant Exercise Proposal &rdquo;); (6) To approve a proposal to adjourn the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Increase In Authorized Shares Proposal and the Warrant Exercise Proposal (the &ldquo; Adjournment Proposal &rdquo;); and (7) To transact such other business as may lawfully come before the meeting or any adjournment thereof. Stockholders of record at the close of business on April 8, 2024, are entitled to notice of and

View Full Filing

View this DEF 14A filing on SEC EDGAR